CEMIP and cancer: Upregulation of KIAA1199 expression is associated with cancer progression and has been reported to predict poor prognosis in various cancers, including colorectal cancer [15], gastric cancer [16], breast cancer [17], non-small cell lung cancer [18], pancreatic cancer [19], hepatocellular carcinoma [20], ovarian cancer [21], and papillary thyroid cancer [22].